An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Mechanism under study
Adds glucagon-receptor agonism (which can raise energy expenditure) to the dual-incretin mechanism, engaging three metabolic pathways simultaneously.
Research-reported dosing
Clinical trials studied slow titration up to ~12 mg weekly. It remains investigational and is not approved for human use.
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
A 2 mg dose ≈ 40 units (50 mcg per unit).
Open this mix in the calculator →Source research-grade Retatrutide ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Retatrutide comparisons
Retatrutide FAQ
What is Retatrutide?
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
What is the half-life of Retatrutide?
Long-acting; trials used once-weekly administration.
What is the research-reported dosing for Retatrutide?
Clinical trials studied slow titration up to ~12 mg weekly. It remains investigational and is not approved for human use.
How is Retatrutide reconstituted?
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
Is Retatrutide FDA-approved?
No — Retatrutide is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Guides featuring Retatrutide
Related peptides
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
MOTS-c
Mitochondrial-derived peptide
A mitochondrial-derived peptide studied as a metabolic regulator and exercise-mimetic in preclinical models, and of interest in aging and insulin-sensitivity research.